Key Points
- Insider sale: Atul Dandekar sold 7,500 Maze Therapeutics shares on Jan. 29 at $44.27 for $332,025, reducing his stake to 10,503 shares (a 41.66% cut).
- Recent pattern of selling: Dandekar also sold 72,400 shares on Dec. 29 at $40.56 ($2.94M) and 100 shares on Dec. 30, meaning his recent insider sales total just over $3.27 million.
- Market context: MAZE is trading near $46.53 (up ~6.8%), has a $2.24B market cap, and carries a consensus analyst rating of "Buy" with a $44.50 target despite mixed analyst views.
Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) insider Atul Dandekar sold 7,500 shares of the company's stock in a transaction dated Thursday, January 29th. The stock was sold at an average price of $44.27, for a total value of $332,025.00. Following the completion of the sale, the insider directly owned 10,503 shares of the company's stock, valued at $464,967.81. The trade was a 41.66% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Atul Dandekar also recently made the following trade(s):
- On Monday, December 29th, Atul Dandekar sold 72,400 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.56, for a total value of $2,936,544.00.
- On Tuesday, December 30th, Atul Dandekar sold 100 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.36, for a total value of $4,036.00.
Maze Therapeutics Stock Up 6.8%
NASDAQ MAZE opened at $46.53 on Tuesday. The stock has a market cap of $2.24 billion and a PE ratio of -2.23. The business has a 50 day moving average price of $41.05 and a two-hundred day moving average price of $29.37. Maze Therapeutics, Inc. has a fifty-two week low of $6.71 and a fifty-two week high of $47.36.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its earnings results on Thursday, November 6th. The company reported ($0.66) EPS for the quarter, topping analysts' consensus estimates of ($0.74) by $0.08.
Hedge Funds Weigh In On Maze Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the business. Ameritas Investment Partners Inc. grew its stake in shares of Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock valued at $42,000 after buying an additional 738 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Maze Therapeutics during the fourth quarter valued at approximately $39,000. Legal & General Group Plc increased its stake in Maze Therapeutics by 23.0% in the third quarter. Legal & General Group Plc now owns 5,219 shares of the company's stock valued at $135,000 after acquiring an additional 977 shares during the period. Bank of America Corp DE raised its stake in Maze Therapeutics by 33.6% during the second quarter. Bank of America Corp DE now owns 5,782 shares of the company's stock worth $71,000 after acquiring an additional 1,455 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in shares of Maze Therapeutics by 947.8% during the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company's stock worth $49,000 after buying an additional 1,725 shares in the last quarter.
Wall Street Analysts Forecast Growth
A number of research analysts have commented on the stock. Lifesci Capital upgraded shares of Maze Therapeutics to a "strong-buy" rating in a research note on Thursday, December 18th. Wedbush raised their price target on Maze Therapeutics from $35.00 to $36.00 and gave the stock an "outperform" rating in a report on Friday, November 7th. Wells Fargo & Company initiated coverage on shares of Maze Therapeutics in a research report on Thursday, December 4th. They issued an "overweight" rating and a $55.00 price objective on the stock. Weiss Ratings reiterated a "sell (d)" rating on shares of Maze Therapeutics in a research report on Thursday, January 22nd. Finally, BTIG Research lifted their price target on Maze Therapeutics from $37.00 to $46.00 and gave the company a "buy" rating in a research report on Friday, January 16th. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $44.50.
Check Out Our Latest Report on Maze Therapeutics
Maze Therapeutics Company Profile
(
Get Free Report)
Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.
Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
